Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04198441
Other study ID # Protocol Number: 100
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date June 2, 2020
Est. completion date December 2021

Study information

Verified date April 2021
Source Omeza, LLC
Contact Luba Lavrik
Phone 561-200-3344
Email LLavrik@PalmBeachCRO.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will compare the Omeza® Products Bundle to standard of care (SOC) for in subjects with chronic venous leg ulcers and subjects with diabetic foot ulcers.


Description:

This is a randomized, multi-center, open-label study comparing the Omeza® Products Bundle versus standard of care treatments for 2 different types of chronic ulcers (venous leg ulcers and diabetic foot ulcers). The treatment period will be 12 weeks, with subjects coming into the study site weekly for evaluations, photography and formal measurements of the target wound, and dressing changes. There will be a total of 13 study site visits. The Screening Visit (Day 0) will occur 1 week prior to randomization and will include routine labs and vascular assessment to determine inclusion/exclusion of the potential subject from the study; followed by weekly treatment visits (Week 1 through Week 11); randomization will occur at Treatment Visit Week 1; the Treatment Visit Week 12/End of Study Visit will include end of study labs. Target wounds will be photographed and measured, and vascular assessment will be done at each of the 13 visits. If the wound closes before Week 12, the subject will continue to come in for all the remaining study visits until study completion. If the wound does not close by Week 12, the subject will be immediately exited from the study and no further follow-up will occur as part of the study.


Recruitment information / eligibility

Status Recruiting
Enrollment 78
Est. completion date December 2021
Est. primary completion date October 2021
Accepts healthy volunteers No
Gender All
Age group 21 Years to 80 Years
Eligibility Inclusion Criteria: 1. Male or female 21-80 years of age 2. Participated in the informed consent process and signed study specific informed consent document 3. Willing and able to comply with study procedures, including study visits and study dressing regimens 4. Confirmation of venous disease by non-invasive venous studies with either Doppler- confirmed venous reflux or having = 2 clinical characteristics of venous insufficiency (varicose veins, lipodermatosclersosis, venous dermatitis, atrophie blanche, edema). Biopsy done to exclude other skin conditions e.g. cancer on ulcers = 6 months 5. HbA1c of = 10% 6. Have a venous ulcer between the knee and ankle, at or above the malleolus 7. For VLU's: Target wound size = 4 cm2 to = 150 cm2 in area without exposed tendon, muscle or bone For DFU's: Target wound size = 0.25 cm2 to = 150 cm2 post debridement at Screening Visit and Treatment Visit Week 1/Randomization 8. Target wound duration of at least 3 months and less than or equal to 12 months as of the date the subject signs consent for study 9. Containing yellow/white slough with or without fibrous/scar tissue and/or non- viable tissue 10. Be willing and able (or have family member/friend willing and able) to apply required dressing changes as well as the ability of the subject to tolerate limb compression bandage 11. Ankle-Branchial Index (ABI) less than 0.80 or greater than 1.3 Exclusion Criteria: 1. Subjects with a BMI = 65 2. Subject is medically unable to consent (due to head trauma, coma, etc.) or cognitively impaired (due to being mentally challenged, having Alzheimer

Study Design


Intervention

Device:
Wound dressing
Clean wound, fill wound, dress wound

Locations

Country Name City State
United States Baylor Scott & White Comprehensive Wound Care Center Dallas Texas
United States First Coast Cardiovascular Institute Jacksonville Florida
United States Saint Michael's Medical Center Newark New Jersey
United States Oregon Health & Science University (OHSU) Portland Oregon

Sponsors (1)

Lead Sponsor Collaborator
Omeza, LLC

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Wound Closure Percent wound closure from baseline 13 weeks
Primary Wound Closure Rate Rate of wound closure measured weekly 13 weeks
Primary Time to Maximum Wound Closure Number of weeks to achieve complete wound closure 1-13 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT04497805 - Clinical Study of ALLO-ASC-SHEET in Subjects With Diabetic Wagner Grade II Foot Ulcers Phase 2
Withdrawn NCT03675269 - Adjunctive Hyperbaric Oxygen Therapy (HBOT) for Lower Extermity Diabetic Ulcer: N/A
Completed NCT04624516 - Effect of Self-foot Exercise on the Incidence of Plantar Foot Diabetic Ulcer Recurrence N/A
Not yet recruiting NCT06439667 - VIRTUALLY SUPERVISED TELE-EXERCISE PLATFORM FOR ACCELERATING PLANTAR WOUND HEALING
Recruiting NCT05608187 - Evaluating Safety and Biological Effect on Wound Healing of ILP100-Topical in Subjects With Diabetic Foot Ulcers Phase 2
Not yet recruiting NCT06437028 - Evaluating the Efficacy of Perinatal Membrane Allografts for the Treatment of Diabetic Foot Ulcers. N/A
Not yet recruiting NCT06278935 - Lifestyle Tailored Offloading for Diabetic Foot Ulcers N/A
Withdrawn NCT05024656 - AmnioExcel® Plus vs SOC in the Management of Diabetic Foot Ulcers N/A
Terminated NCT02202668 - Transcutaneous Raman Spectroscope (TRS) Analyses of Diabetic Foot Ulcers N/A
Completed NCT01951768 - Efficacy and Safety of Garamycin® Sponge in Diabetic Patients With a Moderate or Severe Foot Ulcer Infection Phase 4
Terminated NCT01966380 - Proof of Concept (Design Validation) in Patient With Hard to Heal Wounds Such as Pressure Ulcer, Diabetic Foot Ulcer and Leg Ulcer, Leia Phase 2
Completed NCT01657474 - Comparative Study of Two Application Regimens of Amniotic Membrane Wound Graft In the Management of Diabetic Foot Ulcers N/A
Active, not recruiting NCT00389636 - TheraGauze™ Alone and Regranex®Gel 0.01% Plus TheraGauze™ in the Treatment of Wagner Stage I Diabetic Foot Ulcers N/A
Completed NCT01181440 - Dermagraft(R) for the Treatment of Patients With Diabetic Foot Ulcers Phase 3
Enrolling by invitation NCT05888259 - Plantar Pressure Distribution in Diabetic Foot Ulcer N/A
Completed NCT04054804 - Digital Foot Check by Using the D-Foot, a New Software
Not yet recruiting NCT05877378 - Efficacy of PICO Single-use System in Chronic Ulcers N/A
Recruiting NCT06037369 - The Short Message-based Customized Standardized N/A
Completed NCT03312595 - Clinical Outcomes After Treatment With RestrataTM Wound Matrix in Diabetic Foot Ulcers (DFU) N/A
Recruiting NCT04564443 - A Unique Micro Water Jet Technology Device Versus Standard Debridement in the Treatment of Diabetic Foot N/A